Seeking Alpha

GlaxoSmithKline (GSK) and Theravance (THRX) complete Phase III studies for Relovair to treat...

GlaxoSmithKline (GSK) and Theravance (THRX) complete Phase III studies for Relovair to treat patients with chronic obstructive pulmonary disease, and complete all but one study for the use of Relovair for asthma. GSK plans to submit regulatory applications to U.S. and EU regulators in mid-2012. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs